These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 18958278)

  • 1. Acquisition of growth-inhibitory antibodies against blood-stage Plasmodium falciparum.
    McCallum FJ; Persson KE; Mugyenyi CK; Fowkes FJ; Simpson JA; Richards JS; Williams TN; Marsh K; Beeson JG
    PLoS One; 2008; 3(10):e3571. PubMed ID: 18958278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-mediated growth inhibition of Plasmodium falciparum: relationship to age and protection from parasitemia in Kenyan children and adults.
    Dent AE; Bergmann-Leitner ES; Wilson DW; Tisch DJ; Kimmel R; Vulule J; Sumba PO; Beeson JG; Angov E; Moormann AM; Kazura JW
    PLoS One; 2008; 3(10):e3557. PubMed ID: 18958285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity.
    Singh S; Miura K; Zhou H; Muratova O; Keegan B; Miles A; Martin LB; Saul AJ; Miller LH; Long CA
    Infect Immun; 2006 Aug; 74(8):4573-80. PubMed ID: 16861644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantifying the importance of MSP1-19 as a target of growth-inhibitory and protective antibodies against Plasmodium falciparum in humans.
    Wilson DW; Fowkes FJ; Gilson PR; Elliott SR; Tavul L; Michon P; Dabod E; Siba PM; Mueller I; Crabb BS; Beeson JG
    PLoS One; 2011; 6(11):e27705. PubMed ID: 22110733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of antibodies to Plasmodium falciparum merozoite surface protein-4 with protection against clinical malaria.
    Perraut R; Varela ML; Joos C; Diouf B; Sokhna C; Mbengue B; Tall A; Loucoubar C; Touré A; Mercereau-Puijalon O
    Vaccine; 2017 Dec; 35(48 Pt B):6720-6726. PubMed ID: 29042203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contrasting Patterns of Serologic and Functional Antibody Dynamics to Plasmodium falciparum Antigens in a Kenyan Birth Cohort.
    Dent AE; Malhotra I; Wang X; Babineau D; Yeo KT; Anderson T; Kimmel RJ; Angov E; Lanar DE; Narum D; Dutta S; Richards J; Beeson JG; Crabb BS; Cowman AF; Horii T; Muchiri E; Mungai PL; King CL; Kazura JW
    Clin Vaccine Immunol; 2016 Feb; 23(2):104-16. PubMed ID: 26656119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasmodium falciparum merozoite surface protein 1 (MSP1): genotyping and humoral responses to allele-specific variants.
    Ekala MT; Jouin H; Lekoulou F; Issifou S; Mercereau-Puijalon O; Ntoumi F
    Acta Trop; 2002 Jan; 81(1):33-46. PubMed ID: 11755430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of early life exposure to Plasmodium falciparum on the development of naturally acquired immunity to malaria in young Malawian children.
    Barua P; Beeson JG; Maleta K; Ashorn P; Rogerson SJ
    Malar J; 2019 Jan; 18(1):11. PubMed ID: 30658632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquisition of invasion-inhibitory antibodies specific for the 19-kDa fragment of merozoite surface protein 1 in a transmigrant population requires multiple infections.
    Murhandarwati EE; Black CG; Wang L; Weisman S; Koning-Ward TF; Baird JK; Tjitra E; Richie TL; Crabb BS; Coppel RL
    J Infect Dis; 2008 Oct; 198(8):1212-8. PubMed ID: 18717639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temporal stability of naturally acquired immunity to Merozoite Surface Protein-1 in Kenyan adults.
    Dent AE; Chelimo K; Sumba PO; Spring MD; Crabb BS; Moormann AM; Tisch DJ; Kazura JW
    Malar J; 2009 Jul; 8():162. PubMed ID: 19607717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acquisition of Functional Antibodies That Block the Binding of Erythrocyte-Binding Antigen 175 and Protection Against Plasmodium falciparum Malaria in Children.
    Irani V; Ramsland PA; Guy AJ; Siba PM; Mueller I; Richards JS; Beeson JG
    Clin Infect Dis; 2015 Oct; 61(8):1244-52. PubMed ID: 26136391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Avidity of anti-malarial antibodies inversely related to transmission intensity at three sites in Uganda.
    Ssewanyana I; Arinaitwe E; Nankabirwa JI; Yeka A; Sullivan R; Kamya MR; Rosenthal PJ; Dorsey G; Mayanja-Kizza H; Drakeley C; Greenhouse B; Tetteh KK
    Malar J; 2017 Feb; 16(1):67. PubMed ID: 28183299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural antibody responses to Plasmodium falciparum MSP3 and GLURP(R0) antigens are associated with low parasite densities in malaria patients living in the Central Region of Ghana.
    Amoah LE; Nuvor SV; Obboh EK; Acquah FK; Asare K; Singh SK; Boampong JN; Theisen M; Williamson KC
    Parasit Vectors; 2017 Aug; 10(1):395. PubMed ID: 28835262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High levels of serum antibodies to merozoite surface protein 2 of Plasmodium falciparum are associated with reduced risk of clinical malaria in coastal Kenya.
    Polley SD; Conway DJ; Cavanagh DR; McBride JS; Lowe BS; Williams TN; Mwangi TW; Marsh K
    Vaccine; 2006 May; 24(19):4233-46. PubMed ID: 16111789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction between maternally derived antibodies and heterogeneity in exposure combined to determine time-to-first Plasmodium falciparum infection in Kenyan infants.
    Reynaldi A; Dent AE; Schlub TE; Ogolla S; Rochford R; Davenport MP
    Malar J; 2019 Jan; 18(1):19. PubMed ID: 30670032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of Plasmodium falciparum transmission reducing immunity among primary school children in a malaria moderate transmission region in Zimbabwe.
    Paul NH; Vengesai A; Mduluza T; Chipeta J; Midzi N; Bansal GP; Kumar N
    Acta Trop; 2016 Nov; 163():103-8. PubMed ID: 27491342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Merozoite Surface Protein 1 from Plasmodium falciparum Is a Major Target of Opsonizing Antibodies in Individuals with Acquired Immunity against Malaria.
    Jäschke A; Coulibaly B; Remarque EJ; Bujard H; Epp C
    Clin Vaccine Immunol; 2017 Nov; 24(11):. PubMed ID: 28877929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IgG against Plasmodium falciparum variant surface antigens and growth inhibitory antibodies in Mozambican children receiving intermittent preventive treatment with sulfadoxine-pyrimethamine.
    Quelhas D; Jiménez A; Quintó L; Serra-Casas E; Mayor A; Cisteró P; Puyol L; Wilson DW; Richards JS; Nhampossa T; Macete E; Aide P; Mandomando I; Sanz S; Aponte JJ; Alonso PL; Beeson JG; Menéndez C; Dobaño C
    Immunobiology; 2011 Jul; 216(7):793-802. PubMed ID: 21257227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of transmission intensity and age on subclass antibody responses to Plasmodium falciparum pre-erythrocytic and blood-stage antigens.
    Noland GS; Jansen P; Vulule JM; Park GS; Ondigo BN; Kazura JW; Moormann AM; John CC
    Acta Trop; 2015 Feb; 142():47-56. PubMed ID: 25446174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human IgG subclass antibodies to the 19 kilodalton carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (MSP1(19)) and predominance of the MAD20 allelic type of MSP1 in Uganda.
    Apio B; Nalunkuma A; Okello D; Riley E; Egwang TG
    East Afr Med J; 2000 Apr; 77(4):189-93. PubMed ID: 12858901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.